Onco-Summaries: Daily Oncology Updates at a Glance

12/06/2026

---

• Jazz Pharmaceuticals' Zepzelca Phase 3 LAGOON Trial Misses Primary Endpoint in Second-Line SCLC

  
  

• AbbVie's Venetoclax Shows Sustained 9-Year Efficacy in First-Line CLL at EHA 2026

---

Jazz Pharmaceuticals' Zepzelca Phase 3 LAGOON Trial Misses Primary Endpoint in Second-Line SCLC (Ref)

The Phase 3 LAGOON trial, evaluating Zepzelca (lurbinectedin) in relapsed/second-line metastatic small cell lung cancer (SCLC), did not meet its primary endpoint of overall survival (OS) for either Zepzelca monotherapy or its combination with irinotecan vs the control arm

• Zepzelca monotherapy showed a median OS of 8.7 mos vs 10.7 mos for the control; the Zepzelca + irinotecan arm performed closer to control at 10.9 mos, but neither arm achieved statistical significance

The company has shared the LAGOON results with the FDA and will discuss next steps with the agency regarding its post-marketing requirements for the Zepzelca second-line indication

Return to Top

AbbVie's Venetoclax Shows Sustained 9-Year Efficacy in First-Line CLL at EHA 2026 (Ref)

AbbVie presented final Phase 3 CLL14 trial results at the European Hematology Association (EHA) Congress in Stockholm (June 11–14, 2026), confirming the long-term benefit of venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia (CLL)

After a median follow-up of 9.2 years, the regimen demonstrated significantly superior outcomes over chlorambucil plus obinutuzumab, reinforcing its place as a leading fixed-duration treatment option

• Progression-Free Survival (PFS): Median PFS of 6.4 years (venetoclax + obinutuzumab) vs. 3.2 years (chlorambucil + obinutuzumab) — a 50% reduction in progression risk (HR 0.50)

Return to Top